JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook

Jazz Pharmaceuticals (JAZZ) reported first-quarter 2025 adjusted earnings of $1.68 per share, which significantly missed the Zacks Consensus Estimate of$4.51. This miss was largely due to higher operating expenses incurred during the quarter. Earnings declined 36% year over year.Total revenues declined 0.5% year over year to $897.8 million. The reported figure also missed the Zacks Consensus Estimate of$981 million, attributed to the soft sales performance of its marketed products. (Find the latest EPS es ...